Cholinesterase Inhibitors as Therapy in Alzheimer’s Disease: Benefit to Risk Considerations in Clinical Application

This publication has 18 references indexed in Scilit:

• Double-Blind, Placebo-Controlled Study of Metrifonate, an Acetylcholinesterase Inhibitor, for Alzheimer Disease
  Alzheimer Disease & Associated Disorders, 1996
• Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor.
  Proceedings of the National Academy of Sciences, 1992
• A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
  New England Journal of Medicine, 1992
• Cholinergic Basis for Alzheimer Therapy
  Published by Springer Nature ,1991
• Effects of metrifonate, a long-acting cholinesterease inhibitor, in alzheimer disease: Report of an open trial
  Drug Development Research, 1990
• Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain
  Neuropharmacology, 1989
• Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects
  Drug Development Research, 1988
• Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition: Can acetylcholine levels in the brain be improved in alzheimer's disease?
  Drug Development Research, 1988
• A comparison of the effects of two inhibitors on brain cholinesterase
  Neuropharmacology, 1987
• “Mini-mental state”
  Journal of Psychiatric Research, 1975